Medivir interim report, 1 january -30 june 2001
MEDIVIR INTERIM REPORT, 1 January - 30 June 2001 · Profit after financial items was SEK -68.0 (-33.9) m; net sales increased to SEK 63.6 (54.7) m. · CCS lifted its net sales to SEK 63.8 (41.2) m; operating profit was SEK 9.7 (8.7) m. · Herpes antiviral ME-609: Final Report from the phase II clinical trial showed good efficacy. Strategy for outlicensing and phase III clinical trial strategy established. · Multiresistant-HIV antiviral MIV-310: Authorization to commence phase II clinical trials received. · Good progress in the preclinical portfolio. Forthcoming Reports in 2001 The nine-month